gxh00
Lv5
910 积分
2020-10-16 加入
-
The antibody–drug conjugate landscape
11天前
已完结
-
Thrombolysis for acute ischaemic stroke: current status and future perspectives
14天前
已完结
-
Schizophrenia: from neurochemistry to circuits, symptoms and treatments
16天前
已完结
-
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
17天前
已完结
-
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
1个月前
已完结
-
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial
1个月前
已完结
-
Promising therapies for the treatment of myasthenia gravis
1个月前
已完结
-
Early treatment with an M1 and sigma-1 receptor agonist prevents cognitive decline in a transgenic rat model displaying Alzheimer-like amyloid pathology
1个月前
已完结
-
Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial
2个月前
已完结
-
The JAK-STAT pathway at 30: Much learned, much more to do
3个月前
已完结